Log in

NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price, Forecast & News

$61.13
-1.77 (-2.81 %)
(As of 02/18/2020 04:19 AM ET)
Today's Range
$60.40
Now: $61.13
$64.24
50-Day Range
$42.66
MA: $54.96
$62.90
52-Week Range
$35.41
Now: $61.13
$74.50
Volume510,971 shs
Average Volume402,517 shs
Market Capitalization$3.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.35
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RARE
CUSIPN/A
Phone415-483-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$103.71 million
Book Value$12.04 per share

Profitability

Net Income$-402,730,000.00
Net Margins-388.30%

Miscellaneous

EmployeesN/A
Market Cap$3.53 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.


Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) posted its earnings results on Thursday, February, 13th. The biopharmaceutical company reported ($1.62) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.61) by $0.01. The biopharmaceutical company had revenue of $35.59 million for the quarter, compared to analysts' expectations of $32.31 million. Ultragenyx Pharmaceutical had a negative net margin of 388.30% and a negative return on equity of 49.81%. View Ultragenyx Pharmaceutical's Earnings History.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Ultragenyx Pharmaceutical.

What guidance has Ultragenyx Pharmaceutical issued on next quarter's earnings?

Ultragenyx Pharmaceutical updated its FY 2019 IntraDay earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $102-104 million, compared to the consensus revenue estimate of $100.68 million.

What price target have analysts set for RARE?

11 equities research analysts have issued 1-year target prices for Ultragenyx Pharmaceutical's stock. Their forecasts range from $59.00 to $87.00. On average, they expect Ultragenyx Pharmaceutical's share price to reach $75.09 in the next twelve months. This suggests a possible upside of 22.8% from the stock's current price. View Analyst Price Targets for Ultragenyx Pharmaceutical.

What is the consensus analysts' recommendation for Ultragenyx Pharmaceutical?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ultragenyx Pharmaceutical.

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
  • 1. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019)
  • 2. According to Zacks Investment Research, "Ultragenyx is encouraged by the growing demand for Crysvita from both children and adults, with X-linked hypophosphatemia (XLH) in the United States. The company looks forward to expand the global commercial reach of its approved therapies in 2019. It also expects to file for potential approval of its third therapy, UX007 in fatty acid oxidation disorders in the year. Ultragenyx continues to advance the two gene therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency — with additional data expected to be released in 2019. However, Since Ultragenyx is a newly commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have widened ahead of the Q1 earnings results. The company has a positive record of earnings surprises in recent quarters." (4/23/2019)

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

Headlines about RARE stock have trended somewhat positive recently, according to InfoTrie. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ultragenyx Pharmaceutical earned a news impact score of 1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Ultragenyx Pharmaceutical.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Exelixis (EXEL), Gilead Sciences (GILD), Portola Pharmaceuticals (PTLA), TG Therapeutics (TGTX), GALAPAGOS NV/S (GLPG), Netflix (NFLX), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), Sangamo Therapeutics (SGMO) and Palo Alto Networks (PANW).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.81%), FMR LLC (3.16%), First Trust Advisors LP (2.06%), Franklin Resources Inc. (0.64%), Charles Schwab Investment Management Inc. (0.58%) and Bank of New York Mellon Corp (0.40%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Group AG, Rafferty Asset Management LLC, Candriam Luxembourg S.C.A., Cubist Systematic Strategies LLC, Laurion Capital Management LP, New York State Common Retirement Fund and SG Americas Securities LLC. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Shalini Sharp and Theodore Alan Huizenga. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., First Trust Advisors LP, Pinnacle Associates Ltd., State Street Corp, Barclays PLC, Point72 Asset Management L.P., Rothschild & Co. Asset Management US Inc. and Ikarian Capital LLC. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $61.13.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $3.53 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis. View Additional Information About Ultragenyx Pharmaceutical.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is http://www.ultragenyx.com/.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]


MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  708 (Vote Outperform)
Underperform Votes:  345 (Vote Underperform)
Total Votes:  1,053
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe RARE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RARE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Resistance Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel